



ASX Release

4 January 2008

AVEXA LIMITED (AVX) provides the opportunity to listen to an audio broadcast with **Dr Julian Chick, CEO and Boardroomradio** in a presentation titled “**Avexa Initiates Phase 111 ATC Trial**”

To listen, simply click on the link below:

<http://www.brr.com.au/event/39543>

The presentation details are as follows:

- **Avexa Initiates Phase 111 ATC Trial**
- **Presented by Dr Julian Chick, CEO**
- **January 4 2008 at 9.45 AEST**

Boardroomradio offers many free services, such as:

- [Boardroomradio Alerts](#)
- Easy access to archived presentations on demand
- Podcast subscription with daily updates

Visit <http://www.brr.com.au> for more

For more information:

Dr. Julian Chick
Chief Executive Officer
+61 3 9208 4300

Mr Rod North
Bourse Communications
+ 61 (03) 9510-8309

www.avexa.com.au

Avexa Limited is a Melbourne-based biotechnology company with a focus on research and development of drugs for the treatment of infectious diseases. Avexa has dedicated resources and funding for key projects including its HIV integrase program and an antibiotic program for antibiotic-resistant bacterial infections. The Company's lead program is apricitabine (ATC), an anti-HIV drug which has successfully completed the 24 week dosing of its Phase 2b trial and has initiated the Phase 3 trial. Avexa has entered into a collaboration with TargetDrug in China to identify new CCR5 inhibitors for the treatment of HIV infections and has an exclusive option to license TargetDrug's lead CCR5 inhibitor, nifeviroc.